ACS, Ovarian Cancer Research Alliance form research collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Cancer Society and Ovarian Cancer Research Alliance partnered to fund multidisciplinary research projects to explore new ways of detecting, treating, and preventing ovarian cancer relapse and for improving quality of life among those diagnosed with ovarian cancer.

The two organizations are committing to a total investment of $8 million to sustain four research teams over four years.

The joint initiative seeks to raise funds to support four multidisciplinary research teams to investigate biological, clinical, and psychosocial factors associated with ovarian cancer outcomes. Once initial funding is acquired, a request for proposal/critical peer review process will select the four research teams.

YOU MAY BE INTERESTED IN

FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login